Loading
A phase 2 trial of toripalimab in triple-negative breast cancer, run by First Affiliated Hospital of Zhejiang University, now recruiting.
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) is a phase 2, interventional study registered as NCT06682195 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 35 participants, started 2024-10-09 and due to reach its primary completion in 2026-10-01. Interventions recorded: Neoadjuvant chemotherapy combined with Toripalimab. Conditions listed: TNBC, Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "All patients had triple negative breast cancer confirmed by histopathology;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.